비교리스트

 카트 문의
시장보고서
상품코드
1424066

세계 첨단 치료제(ATMP) CDMO 시장 - 점유율, 규모, 동향, 산업 분석 보고서 : 제품별, 위상별, 적응증별, 지역별 부문 예측(2024-2032년)

Advanced Therapy Medicinal Products CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others); By Phase; By Indication; By Region; Segment Forecast, 2024 - 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면 세계 첨단 치료제(ATMP) CDMO 시장 규모는 2032년까지 262억 7,000만 달러에 달할 전망입니다. 이 보고서는 현재 시장 역학을 상세하게 통찰하고 미래 시장 성장에 대한 분석을 제공합니다.

인구간에 수많은 질병이 진화하고 만성적인 건강 문제를 일반적인 의약품으로 치료할 수 있게 되었기 때문에 연구자나 정부 기관은 유전자 의료나 세포·조직 요법에 대한 투자를 강요받게 된다 있습니다. 이러한 지속적인 동향은 제약 기업이 새로운 치료법을 혁신하기에 적합한 환경을 촉진하고, 새로운 치료법의 개발, 시험, 제조에 필요한 인프라를 가진 조직의 필요성을 촉진하고, 개발 및 제조 수탁기관(CDMO)의 지원이 필요합니다.

제약 산업을 규제하는 정부 이니셔티브 증가는 첨단 치료제(ATMP) CDMO 시장의 성장 기회에 긍정적인 영향을 보여줍니다. 2023년 9월 영국 CDMO인 Rentschler Biopharma SE는 Medicines & Healthcare Products Regulatory Agency로부터 바이오프로세스 및 cGMP 생산을 포함한 유전자 치료용 아데노 관련 바이러스 벡터(AAV)를 개발·공급하는 허가를 취득 했습니다.

건강 문제를 치료하기 위해 R&D 활동을 확대하기 위한 전략적 공동 연구 및 파트너십 신흥국 시장은 ATMP CDMO 시장에 긍정적인 영향을 미치고 있습니다. Histocell과의 제휴를 통해 Reprocell은 중간엽 줄기세포에서 생산되는 고급 치료제 및 의약품을 생산하게 됩니다.

세포 치료와 유전자 치료의 생산은 시장에서 긍정적인 전망을 보여줍니다. Gene, Cell, &RNA Therapy Landscape Report에 따르면, 2023년 3분기에는 27개의 유전자 치료, 26개의 RNA 치료, 65개의 비유전자 재조합 세포 치료가 임상 사용의 승인을 받았습니다. 1상 임상시험을 실시하고 있는 유전자 치료제의 총수는 3분기는 1분기에 비해 7% 증가했습니다. 이러한 추세는 첨단 의료용 의약품을 생산할 수 있는 잠재적인 수요를 보여주며 앞으로 수년간 CDMO의 필요성을 높이고 있습니다.

조직공학산업은 마켓플레이스에서 기세를 늘리고 있습니다. 그것의 원동력은 조직의 대체, 수리 및 재생에 대한 깊은 범위이며 피부, 심장, 간, 폐 조직 관련 건강 문제를 치료하는 데 사용됩니다. 조직 공학적 치료법 개발에 대한 연구 활동 증가는 첨단 치료제 CDMO 시장을 견인할 것으로 기대됩니다.

첨단 치료제(ATMP) CDMO 시장 보고서 하이라이트

유전자 치료에 대한 임상시험 증가로 인해 유전자 치료 분야는 향후 몇 년동안 가장 높은 성장이 예상됩니다.

치료 개발 횟수가 증가함에 따라 i상 시장은 최대 수익 점유율을 차지했습니다.

암 환자수 증가와 그 다양한 형태에 의해 암 영역이 최대의 점유율을 차지했습니다.

아시아태평양은 예측 기간 동안 가장 빠른 성장을 기록할 것으로 예상되며, 이는 세포 치료와 유전자 치료에 대한 투자 증가로 인한 것입니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 첨단 치료제(ATMP) CDMO 시장 인사이트

  • 첨단 치료제(ATMP) CDMO 시장 - 위상 스냅샷
  • 첨단 치료제(ATMP) CDMO 시장 역학
    • 성장 촉진요인과 기회
      • 생명 공학에서 세포 및 유전자 기반 치료의 시작
      • CDMO의 높은 생산 능력
    • 억제요인과 과제
      • ATMP 생산과 관련된 인력 부족은 시장 성장을 방해할 가능성이 높음
  • PESTEL 분석
  • 첨단 치료제 CDMO 시장 단계의 동향
  • 밸류체인 분석
  • COVID-19 감염의 영향 분석

제5장 세계의 첨단 치료제(ATMP) CDMO 시장, 적응증별

  • 주요 조사 결과
  • 소개
  • 종양학
  • 심장병학
  • 중추신경계
  • 근골격계
  • 감염증
  • 피부과
  • 내분비, 대사, 유전
  • 면역학과 염증
  • 안과
  • 혈액학
  • 소화기과
  • 기타

제6장 세계의 첨단 치료제(ATMP) CDMO 시장, 제품별

  • 주요 조사 결과
  • 소개
  • 세포치료
  • 유전자 치료

제7장 세계의 첨단 치료제(ATMP) CDMO 시장, 위상별

  • 주요 조사 결과
  • 소개
  • 페이즈 I
  • 페이즈 II
  • 페이즈Ⅲ
  • 페이즈 IV

제8장 세계의 첨단 치료제(ATMP) CDMO 시장, 지역별

  • 주요 조사 결과
  • 소개
    • 첨단 치료제(ATMP) CDMO 시장 평가, 지역별(2019-2032년)
  • 첨단 치료제(ATMP) CDMO 시장 - 북미
    • 북미 : 첨단 치료제(ATMP) CDMO 시장, 적응증별(2019-2032년)
    • 북미 : 첨단 치료제(ATMP) CDMO 시장, 페이즈별(2019-2032년)
    • 북미 : 첨단 치료제(ATMP) CDMO 시장, 제품별(2019-2032년)
    • 첨단 치료제(ATMP) CDMO 시장 - 미국
    • 첨단 치료제(ATMP) CDMO 시장 - 캐나다
  • 첨단 치료제(ATMP) CDMO 시장 - 유럽
    • 유럽 : 첨단 치료제(ATMP) CDMO 시장, 적응증별(2019-2032년)
    • 유럽 : 첨단 치료제(ATMP) CDMO 시장, 페이즈별(2019-2032년)
    • 유럽 : 첨단 치료제(ATMP) CDMO 시장, 제품별(2019-2032년)
    • 첨단 치료제(ATMP) CDMO 시장 - 영국
    • 첨단 치료제(ATMP) CDMO 시장 - 프랑스
    • 첨단 치료제(ATMP) CDMO 시장 - 독일
    • 첨단 치료제(ATMP) CDMO 시장 - 이탈리아
    • 첨단 치료제(ATMP) CDMO 시장 - 스페인
    • 첨단 치료제(ATMP) CDMO 시장 - 네덜란드
    • 첨단 치료제(ATMP) CDMO 시장 - 러시아
  • 첨단 치료제(ATMP) CDMO 시장 - 아시아태평양
    • 아시아태평양 : 첨단 치료제(ATMP) CDMO 시장, 적응증별(2019-2032년)
    • 아시아태평양 : 첨단 치료제(ATMP) CDMO 시장, 위상별(2019-2032년)
    • 아시아태평양 : 첨단 치료제(ATMP) CDMO 시장, 제품별(2019-2032년)
    • 첨단 치료제(ATMP) CDMO 시장 - 중국
    • 첨단 치료제(ATMP) CDMO 시장 - 인도
    • 첨단 치료제(ATMP) CDMO 시장 - 말레이시아
    • 첨단 치료제(ATMP) CDMO 시장 - 일본
    • 첨단 치료제(ATMP) CDMO 시장 - 인도네시아
    • 첨단 치료제(ATMP) CDMO 시장 - 한국
  • 첨단 치료제(ATMP) CDMO 시장 - 중동 및 아프리카
    • 중동 및 아프리카 : 첨단 치료제(ATMP) CDMO 시장, 적응증별(2019-2032년)
    • 중동 및 아프리카 : 첨단 치료제(ATMP) CDMO 시장, 위상별(2019-2032년)
    • 중동 및 아프리카 : 첨단 치료제(ATMP) CDMO 시장, 제품별(2019-2032년)
    • 첨단 치료제(ATMP) CDMO 시장 - 사우디아라비아
    • 첨단 치료제(ATMP) CDMO 시장 - 아랍에미리트(UAE)
    • 첨단 치료제(ATMP) CDMO 시장 - 이스라엘
    • 첨단 치료제(ATMP) CDMO 시장 - 남아프리카
  • 첨단 치료제(ATMP) CDMO 시장 - 라틴아메리카
    • 라틴아메리카 : 첨단 치료제(ATMP) CDMO 시장, 적응증별(2019-2032년)
    • 라틴아메리카 : 첨단 치료제(ATMP) CDMO 시장, 페이즈별(2019-2032년)
    • 라틴아메리카 : 첨단 치료제(ATMP) CDMO 시장, 제품별(2019-2032년)
    • 첨단 치료제(ATMP) CDMO 시장 - 멕시코
    • 첨단 치료제(ATMP) CDMO 시장 - 브라질
    • 첨단 치료제(ATMP) CDMO 시장 - 아르헨티나

제9장 경쟁 구도

  • 확장 및 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 프로파일

  • AGC Biologics(Switzerland)
  • Bio Elpida(France)
  • BlueReg(France)
  • Catalent(US)
  • Celonic(Switzerland)
  • CGT Catapult(UK)
  • Lonza(Switzerland)
  • Medicine Patheon(US)
  • Minaris Regenerative(US)
  • Rentschler Biopharma SE(US)
  • WuXi Advanced Therapies(US)
JHS 24.02.28

The global advanced therapy medicinal products CDMO market size is expected to reach USD 26.27 billion by 2032, according to a new study by Polaris Market Research. The report "Advanced Therapy Medicinal Products CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others); By Phase; By Indication; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The evolution of numerous diseases among the population and the ability to cure chronic health issues with the prevailing medicines is compelling researchers and government institutions to invest in genetic medicine and cell and tissue therapies. This ongoing trend is facilitating a compatible environment for pharmaceutical companies to innovate new therapies, driving the need for organizations that have the required infrastructure for the development, testing, and manufacturing of new therapies, necessitating the assistance of contract development and manufacturing organizations (CDMO).

The rising government initiatives to regulate the pharmaceutical industry are showing a positive impact on the advanced therapy medicinal products CDMO market growth opportunities. In September 2023, UK CDMO Rentschler Biopharma SE received approval to develop and supply adeno-associated virus vectors (AAV) for gene therapy, including bioprocessing and cGMP production, from the Medicines & Healthcare Products Regulatory Agency.

The growing strategic collaborations and partnerships to expand the research and development activities towards treating health problems are positively influencing the ATMP CDMO market. With the Histocell partnership, Reprocell will produce advanced therapies and medicinal products generated from mesenchymal stem cells.

Cell and gene therapy production is showing a positive outlook in the market. According to the Gene, Cell, & RNA Therapy Landscape Report, in Q3 2023, 27 gene therapies, 26 RNA therapies, and 65 non-genetically modified cell therapies, received approval for clinical use. The total number of gene therapies in phase 1 Q3 registered growth by 7% compared to Q1. This trend is demonstrating the potential demand to produce advanced therapeutic medicinal products, boosting the need for CDMO in the coming years.

The tissue engineering industry is gaining momentum in the marketplace, driven by its profound scope in the replacement, repair, and regeneration of tissues, which are used to cure skin, heart, liver, and lung tissue-related health problems. The rising research activities on the development of tissue engineering therapies are expected to drive the advanced therapy medicinal products CDMO market.

Advanced Therapy Medicinal Products CDMO Market Report Highlights

Gene therapy segment is anticipated to witness the highest growth in the coming years due to the increasing clinical trials on gene therapies.

Phase I segment accounted for the largest revenue share, owing to the rise in number of therapeutic developments.

Oncology segment held the largest share, due to the rising number of cancer patients and its varied forms

Asia pacific is projected to register the fastest growth during the forecast period, attributable to the growing investments in cell and gene therapies.

The global players include AGC Biologics, Bio Elpida, BlueReg, Catalent, Celonic, CGT Catapult, Lonza, Medicine Patheon, & Minaris Regenerative.

Polaris Market Research has segmented the advanced therapy medicinal products CDMO market report based on product, phase, indication and region:

Advanced Therapy Medicinal Products CDMO, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Cell Therapy
  • Gene Therapy

Advanced Therapy Medicinal Products CDMO, Phase Outlook (Revenue - USD Billion, 2019 - 2032)

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Advanced Therapy Medicinal Products CDMO, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Cardiology
  • Central nervous system
  • Musculoskeletal
  • Infectious disease
  • Dermatology
  • Endocrine, metabolic, genetic
  • Immunology & inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others

Advanced Therapy Medicinal Products CDMO, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Advanced Therapy Medicinal Products CDMO Market Insights

  • 4.1. Advanced Therapy Medicinal Products CDMO Market - Phase Snapshot
  • 4.2. Advanced Therapy Medicinal Products CDMO Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The rising cell and gene-based therapies in biotechnology
      • 4.2.1.2. The higher production capability of CDMOs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The talent shortage pertaining to ATMP production is likely to impede market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Advanced Therapy Medicinal Products CDMO Market Phase Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Advanced Therapy Medicinal Products CDMO Market, by Indication

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • 5.3. Oncology
    • 5.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 5.4. Cardiology
    • 5.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Cardiology, by Region, 2019-2032 (USD Billion)
  • 5.5. Central nervous system
    • 5.5.1. Global Advanced Therapy Medicinal Products CDMO Market, by Central nervous system, by Region, 2019-2032 (USD Billion)
  • 5.6. Musculoskeletal
    • 5.6.1. Global Advanced Therapy Medicinal Products CDMO Market, by Musculoskeletal, by Region, 2019-2032 (USD Billion)
  • 5.7. Infectious disease
    • 5.7.1. Global Advanced Therapy Medicinal Products CDMO Market, by Infectious disease, by Region, 2019-2032 (USD Billion)
  • 5.8. Dermatology
    • 5.8.1. Global Advanced Therapy Medicinal Products CDMO Market, by Dermatology, by Region, 2019-2032 (USD Billion)
  • 5.3. Endocrine, metabolic, genetic
    • 5.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Endocrine, metabolic, genetic, by Region, 2019-2032 (USD Billion)
  • 5.4. Immunology & inflammation
    • 5.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Immunology & inflammation, by Region, 2019-2032 (USD Billion)
  • 5.5. Ophthalmology
    • 5.5.1. Global Advanced Therapy Medicinal Products CDMO Market, by Ophthalmology, by Region, 2019-2032 (USD Billion)
  • 5.6. Hematology
    • 5.6.1. Global Advanced Therapy Medicinal Products CDMO Market, by Hematology, by Region, 2019-2032 (USD Billion)
  • 5.7. Gastroenterology
    • 5.7.1. Global Advanced Therapy Medicinal Products CDMO Market, by Gastroenterology, by Region, 2019-2032 (USD Billion)
  • 5.8. Others
    • 5.8.1. Global Advanced Therapy Medicinal Products CDMO Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Advanced Therapy Medicinal Products CDMO Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 6.3. Cell Therapy
    • 6.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Cell Therapy, by Region, 2019-2032 (USD Billion)
  • 6.4. Gene Therapy
    • 6.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Gene Therapy, by Region, 2019-2032 (USD Billion)

7. Global Advanced Therapy Medicinal Products CDMO Market, by Phase

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • 7.3. Phase I
    • 7.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase I, By Region, 2019-2032 (USD Billion)
  • 7.4. Phase II
    • 7.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase II, By Region, 2019-2032 (USD Billion)
  • 7.5. Phase III
    • 7.5.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase III, By Region, 2019-2032 (USD Billion)
  • 7.6. Phase IV
    • 7.6.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase IV, By Region, 2019-2032 (USD Billion)

8. Global Advanced Therapy Medicinal Products CDMO Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Advanced Therapy Medicinal Products CDMO Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Advanced Therapy Medicinal Products CDMO Market - North America
    • 8.3.1. North America: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.3.2. North America: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.3.3. North America: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.3.4. Advanced Therapy Medicinal Products CDMO Market - U.S.
      • 8.3.4.1. U.S.: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.3.5. Advanced Therapy Medicinal Products CDMO Market - Canada
      • 8.3.5.1. Canada: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.4. Advanced Therapy Medicinal Products CDMO Market - Europe
    • 8.4.1. Europe: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.4. Advanced Therapy Medicinal Products CDMO Market - UK
      • 8.4.4.1. UK: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.5. Advanced Therapy Medicinal Products CDMO Market - France
      • 8.4.5.1. France: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.6. Advanced Therapy Medicinal Products CDMO Market - Germany
      • 8.4.6.1. Germany: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.7. Advanced Therapy Medicinal Products CDMO Market - Italy
      • 8.4.7.1. Italy: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.8. Advanced Therapy Medicinal Products CDMO Market - Spain
      • 8.4.8.1. Spain: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.9. Advanced Therapy Medicinal Products CDMO Market - Netherlands
      • 8.4.9.1. Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.10. Advanced Therapy Medicinal Products CDMO Market - Russia
      • 8.4.10.1. Russia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.5. Advanced Therapy Medicinal Products CDMO Market - Asia Pacific
    • 8.5.1. Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.4. Advanced Therapy Medicinal Products CDMO Market - China
      • 8.5.4.1. China: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.5. Advanced Therapy Medicinal Products CDMO Market - India
      • 8.5.5.1. India: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.6. Advanced Therapy Medicinal Products CDMO Market - Malaysia
      • 8.5.6.1. Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.7. Advanced Therapy Medicinal Products CDMO Market - Japan
      • 8.5.7.1. Japan: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.8. Advanced Therapy Medicinal Products CDMO Market - Indonesia
      • 8.5.8.1. Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.9. Advanced Therapy Medicinal Products CDMO Market - South Korea
      • 8.5.9.1. South Korea: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.6. Advanced Therapy Medicinal Products CDMO Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.4. Advanced Therapy Medicinal Products CDMO Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.5. Advanced Therapy Medicinal Products CDMO Market - UAE
      • 8.6.5.1. UAE: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.6. Advanced Therapy Medicinal Products CDMO Market - Israel
      • 8.6.6.1. Israel: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.7. Advanced Therapy Medicinal Products CDMO Market - South Africa
      • 8.6.7.1. South Africa: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.7. Advanced Therapy Medicinal Products CDMO Market - Latin America
    • 8.7.1. Latin America: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.7.4. Advanced Therapy Medicinal Products CDMO Market - Mexico
      • 8.7.4.1. Mexico: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.7.5. Advanced Therapy Medicinal Products CDMO Market - Brazil
      • 8.7.5.1. Brazil: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.7.6. Advanced Therapy Medicinal Products CDMO Market - Argentina
      • 8.7.6.1. Argentina: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AGC Biologics (Switzerland)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bio Elpida (France)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. BlueReg (France)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Catalent (US)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Celonic (Switzerland)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. CGT Catapult (UK)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Lonza (Switzerland)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Medicine Patheon (US)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Minaris Regenerative (US)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Rentschler Biopharma SE (US)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. WuXi Advanced Therapies (US)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제